American Century Companies Inc. Acquires 521,683 Shares of SiBone $SIBN

American Century Companies Inc. boosted its position in SiBone (NASDAQ:SIBN) by 22.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,838,107 shares of the company’s stock after acquiring an additional 521,683 shares during the quarter. American Century Companies Inc. owned 6.58% of SiBone worth $41,777,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in SIBN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of SiBone by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after purchasing an additional 1,053 shares during the period. State of Alaska Department of Revenue bought a new position in shares of SiBone during the 3rd quarter worth about $39,000. State of Wyoming acquired a new stake in shares of SiBone in the 2nd quarter valued at about $55,000. Tower Research Capital LLC TRC increased its position in SiBone by 198.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,897 shares of the company’s stock valued at $92,000 after buying an additional 3,258 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in SiBone in the 2nd quarter valued at about $68,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.

SiBone Price Performance

SIBN opened at $13.83 on Friday. The firm has a 50-day moving average price of $16.88 and a 200-day moving average price of $16.80. SiBone has a twelve month low of $12.49 and a twelve month high of $21.89. The company has a quick ratio of 7.21, a current ratio of 8.55 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $610.87 million, a price-to-earnings ratio of -31.43 and a beta of 0.69.

SiBone (NASDAQ:SIBN) last posted its earnings results on Monday, February 23rd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.09. The firm had revenue of $56.35 million for the quarter, compared to the consensus estimate of $56.26 million. SiBone had a negative return on equity of 11.01% and a negative net margin of 9.41%. Equities analysts expect that SiBone will post -0.78 EPS for the current year.

Insider Activity

In other news, Director Jeffrey W. Dunn sold 20,000 shares of the company’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $21.28, for a total transaction of $425,600.00. Following the sale, the director directly owned 80,115 shares in the company, valued at $1,704,847.20. This represents a 19.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Michael A. Pisetsky sold 20,756 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $15.35, for a total transaction of $318,604.60. Following the completion of the sale, the senior vice president directly owned 285,974 shares in the company, valued at approximately $4,389,700.90. The trade was a 6.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 247,653 shares of company stock valued at $4,234,702. 4.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on SIBN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a report on Monday, December 29th. Morgan Stanley upped their target price on SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Needham & Company LLC increased their target price on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Canaccord Genuity Group lifted their price target on shares of SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, TD Cowen boosted their price target on shares of SiBone from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.67.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.